BioLabs’ Post

I was pleased to share my thoughts on how biotech and pharma can become an early innovation partner of choice during a panel at #BIO2024 alongside Helena Chaye, CEO of our partner @KaliVir Immunotherapeutics, Olga Granaturova, President of PriveBio, Anna Chen, Principal, Frazier Life Sciences and David Kane, Arc Bio Communications, an IQVIA business. For me, three points stood out:    Strategic fit is all important, regardless of asset stage. It is the foundation for a successful partnership.   Communicate the whole value proposition. Alongside data, value can be demonstrated through people, advisors and scientific talent, unique capabilities or a differentiated asset strategy. A well-considered vision for the future is also key.   It’s never too early to start a conversation. The strongest partnerships are underpinned by mutual understanding and respectful, ongoing communication.    At @Astellas Pharma, innovation partnerships play a critical role in accelerating our progress in novel modalities, as we strive to deliver transformative VALUE to patients. Learn more here: https://lnkd.in/dd8tRfgB    #ScienceFirstForPatients #ChangingTomorrow 

In case you missed it, check out our top 3 biotech takeaways from the 42nd Annual JP Morgan Healthcare Conference. #JPM2024 #JPMHealthcare #Biotech #BiotechInnovation #InizioEvokeComms #PharmaComms #HealthcareComms

JP Morgan Healthcare Conference was a great way to kick off 2024! It was wonderful to spend time in beautiful San Francisco, reconnecting with valued colleagues and making new friends. We had exciting meetings with partners and innovators interested in leveraging our cutting-edge capabilities in design, protein engineering, cell line development, immunogenicity, bioconjugate development, and GMP manufacturing. Despite the challenges of a difficult financial environment, we remain committed to drug development in advanced therapeutic modalities such as optimized siRNA Oligo Drug Conjugates (ODC), Antibody Drug Conjugates (ADC). These innovative therapeutics have taken root, like trees planted next to a mighty precision medicine river. As more precision therapeutic medicines advance in the clinic, we will benefit from both our successes and our failures. We are also excited to see how AI is contributing and will revolutionize our industry, enabling rational target discovery, understanding new targets, and identifying patient populations that will benefit from targeted therapeutics. Continuous improvement, operational excellence, and standardization in CMC will drive innovation, improve product quality & safety for patients. Peace and blessings to you all! #JPMorganHealthcareConference #AdvancedTherapeuticModalities #ContinuousImprovement #Partnerships #Innovation #PatientSafety

🌟 Exciting News! 🌟 We are thrilled to share that our CEO & Co-Founder, LakshmiDevi Ethirajan, will be moderating a panel at the 20th BioPharma Nexus Conference in San Diego. The panel discussion will focus on "Advancing Hit Discovery for Complex and Emerging Targets. Join us in San Diego on May 8-9 to gain insights from industry leaders and see how innovations are shaping the future of #DrugDiscovery!

The drug discovery market is booming, with market size surging from $98.01B in 2023 to $111.48B in 2024 (CAGR: 13.7%). Key drivers include advancements in genomics, proteomics, and biopharmaceuticals. Projected to reach $192.2B by 2028 (CAGR: 14.6%), growth is fueled by precision medicine and personalized therapies. Major players ae like Pfizer Inc., Merck., Novartis, Thermo Fisher Scientific Inc. Read more https://lnkd.in/gMBPvC46 #DrugDiscovery #HealthcareInnovation #PrecisionMedicine #Biotech #Pharma #FutureOfMedicine #AI #Genomics #Proteomics #HealthcareExpenditure #tbrc #thebusinessresearchcompany

Highlighting the recent BIO International Convention in San Diego, this Forbes piece touches on an important consideration for any leader in biotech: the notion that "time is your enemy." This industry has no shortage of ambition -- every company I've come across has commendable and inspiring goals to bridge treatment gaps, revolutionize drug delivery, etc. The thing is, we've been having very similar conversations for several years on end, with only a handful of companies demonstrating actual results In that way, I agree that time is our worst enemy. In the words of Bluerock Therapeutics Seth Ettenberg, "Effective prioritization is essential," and learning to focus our efforts in our journey to change medicine. Would love to hear others' thoughts here. #Biotech #DrugDiscovery #NewMedicines

GSK set to buy Aiolos Bio for $1.4B! Wow that was fast... Aiolos only closed its mammoth $245M Series A in October 2023. Another great news story for early Biotech buyouts, and hopefully something else that VC investors can get excited about. Aiolos is a clinical-stage company developing innovative therapies for respiratory and inflammatory conditions. AIO-001, which is ready to enter phase 2 trials for adult asthma patients, represents a potentially best-in-class medicine targeting the TSLP pathway. A nice bolt-on deal for GSK, which already generates $14B+ in revenue from its respiratory medicines and vaccines (2022), and hopefully more encouraging news for asthma patients. 2024 is warming up! #respiratory #asthma #mergersandacquisitions https://lnkd.in/gHJDKN2B

In the ever-evolving healthcare landscape, where decisions shape outcomes and information is crucial, digital channels play a key role in accessing essential product data. We were thrilled to recognize SpringWorks Therapeutics for their exceptional dedication to innovation and outstanding accomplishments, presenting them with the FormularyDecisions Innovation and Impact Award in the Emerging Biopharma category, during AMCP Annual 2024. Watch this interview featuring Zack McCormack, Director of Value and Access at SpringWorks Therapeutics, and Jasmine Knight, Senior Director of Digital Solutions at Cencora, and gain insights into SpringWorks Therapeutics' digital engagement strategy with healthcare decision makers, and the pivotal role played by FormularyDecisions in their digital approach. https://ow.ly/B5VA50SXzlK

🔍 Navigating the complexities of pharma deals? Join the 'Pharma Dealmakers Panel: Viewing the Challenges from Both Sides' at #Sachs_ELSF on February 29th, 2024, at the Hilton Zurich Airport Hotel. A deep dive into the intricacies of biopharma collaborations and negotiations. 🌐🤝 Chaired by: Sarah Holland, President of Swiss HLG & CBO, Cureteq AG - a Partex Company Panellists: Alessandra Polara, Senior Director, Global BD, F. Hoffmann-La Roche AG David Colpman, Director, Alpina Life Science Advisors Emin Fadillioglu, MD, CEO, Eczacıbaşı Topluluğu Pharmaceutical and Industrial Investment Co. Peter L. Braun, CEO, TargImmune Therapeutics AG Ulrich Wendt, Global Head Business Development Immunology & Inflammation, Sanofi Gain unparalleled insights into the challenges and strategies of pharma dealmaking from the perspectives of both biotech innovators and pharma giants. This panel is a must-attend for those looking to understand the dynamics of successful partnerships and investments in the rapidly evolving life sciences landscape. Don’t miss out on this opportunity to network with industry leaders and strategize for success. Register today at www.sachsforum.com/17elsf and be part of the conversation #inperson & #online during the Sachs Spring Life Sciences Week. #PharmaDealmakers #Biopharma #LifeSciences #StrategicPartnerships #InvestmentStrategies #BiotechInnovation #PharmaIndustry #SachsForum #Sachs_ELSF #SachsSpringLifeSciencesWeek #SSLSW